March 3, 2026The Oncologist1 citationsOpen Access

A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2− breast cancer in China

QOQuchang OuyangHunan Cancer Hospital PYPeng YuanChinese Academy of Medical Sciences & Peking Union Medical College JLJianxia LiuSoochow University

Key Points

Abemaciclib showed consistent effectiveness in treating HR+/HER2- breast cancer, indicating a favorable benefit-risk profile.
Participants in the analysis included adults with early and advanced breast cancer who received abemaciclib for treatment.
This observational study evaluated the safety and tolerability of abemaciclib, validating its use in a real-world context.
The findings support the continued use of abemaciclib, emphasizing its positive real-world outcomes without new safety concerns.

Abstract

Real-world safety, tolerability, and effectiveness of abemaciclib in Chinese patients with HR+/HER2- EBC and ABC were consistent with clinical trials, with no new safety signals, supporting its positive real-world benefit-risk profile.

AI에게 질문

Bookmark

View Full Paper